Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 17-Sep-24 6:20 PM View:  | Esposito Pamela Director | Kymera Therapeutics, Inc. (KYMR) | 17-Sep-24 | Option Exercise | 13,500 | $23.86 | $322,075.00 | 100% 0 to 13.5K | |
| 17-Sep-24 6:20 PM View: | Esposito Pamela Director | Kymera Therapeutics, Inc. (KYMR) | 17-Sep-24 | Planned Option Sale | 13,500 | $48.28 | $651,766.00 | (100%) 13.5K to 0 | |
| 26-Aug-24 6:31 PM View: | Albers Jeffrey W. Director | Kymera Therapeutics, Inc. (KYMR) | 26-Aug-24 | Option Exercise | 5,000 | $10.34 | $51,700.00 | 100% 0 to 5.0K | |
| 26-Aug-24 6:31 PM View: | Albers Jeffrey W. Director | Kymera Therapeutics, Inc. (KYMR) | 26-Aug-24 | Planned Option Sale | 5,000 | $49.10 | $245,508.00 | (100%) 5.0K to 0 | |
| 22-Aug-24 4:03 PM View: | Baker Bros Advisors LLC Director | Kymera Therapeutics, Inc. (KYMR) | 20-Aug-24 | Private Purchase | 1 | $46.41 | $46.41 | < 1% 6.0M to 6.0M | |
| 16-Jul-24 6:00 PM View: | Gollob Jared Chief Medical Officer | Kymera Therapeutics, Inc. (KYMR) | 16-Jul-24 | Planned Option Sale | 23,145 | $45.81 | $1,060,220.00 | (20%) 118.61K to 95.47K | |
| 16-Jul-24 6:00 PM View: | Gollob Jared Chief Medical Officer | Kymera Therapeutics, Inc. (KYMR) | 16-Jul-24 | Option Exercise | 23,145 | $2.08 | $48,141.60 | 24% 95.47K to 118.61K | |
| 16-Jul-24 6:00 PM View: | Gollob Jared Chief Medical Officer | Kymera Therapeutics, Inc. (KYMR) | 15-Jul-24 | Planned Option Sale | 16,455 | $45.15 | $742,925.00 | (15%) 112.19K to 95.74K | |
| 16-Jul-24 6:00 PM View: | Gollob Jared Chief Medical Officer | Kymera Therapeutics, Inc. (KYMR) | 15-Jul-24 | Option Exercise | 16,455 | $2.08 | $34,226.40 | 17% 95.74K to 112.19K | |
| 09-Jul-24 5:15 PM View: | Booth Bruce Director | Kymera Therapeutics, Inc. (KYMR) | 09-Jul-24 | Sale (Planned) | 453,960 | $38.21 | $17,346,900.00 | (8%) 5.35M to 4.9M | |
| 28-Jun-24 8:30 AM View: | Jacobs Bruce N. Chief Financial Officer | Kymera Therapeutics, Inc. (KYMR) | 27-Jun-24 | Option Exercise | 25,000 | $2.08 | $52,000.00 | 17% 143.55K to 168.55K | |
| 20-Jun-24 8:30 AM View: | Mainolfi Nello Chief Executive Officer Director | Kymera Therapeutics, Inc. (KYMR) | 18-Jun-24 | Option Exercise | 14,413 | $2.08 | $29,979.00 | 2% 616.77K to 631.19K | |
| 14-Jun-24 6:01 PM View: | Booth Bruce Director | Kymera Therapeutics, Inc. (KYMR) | 13-Jun-24 | Sale (Planned) | 10,200 | $34.98 | $356,796.00 | (< 1%) 5.36M to 5.35M | |
| 14-Jun-24 6:01 PM View: | Booth Bruce Director | Kymera Therapeutics, Inc. (KYMR) | 12-Jun-24 | Sale (Planned) | 16,740 | $35.45 | $593,378.00 | (< 1%) 5.38M to 5.36M | |
| 07-Jun-24 6:36 PM View: | Horobin Joanna Director | Kymera Therapeutics, Inc. (KYMR) | 07-Jun-24 | Option Exercise | 8,500 | $2.08 | $17,680.00 | 100% 0 to 8.5K | |
| 07-Jun-24 6:36 PM View: | Horobin Joanna Director | Kymera Therapeutics, Inc. (KYMR) | 07-Jun-24 | Planned Option Sale | 8,500 | $32.99 | $280,400.00 | (100%) 8.5K to 0 | |
| 23-May-24 4:10 PM View: | Chadwick Jeremy G Chief Operating Officer | Kymera Therapeutics, Inc. (KYMR) | 23-May-24 | Sale | 2,575 | $34.99 | $90,104.70 | (6%) 46.76K to 44.18K | |
| 15-Mar-24 7:23 PM View: | Booth Bruce Director | Kymera Therapeutics, Inc. (KYMR) | 15-Mar-24 | Sale (Planned) | 71,764 | $40.46 | $2,903,340.00 | (1%) 5.45M to 5.38M | |
| 15-Mar-24 7:23 PM View: | Booth Bruce Director | Kymera Therapeutics, Inc. (KYMR) | 14-Mar-24 | Sale (Planned) | 55,779 | $39.98 | $2,229,930.00 | (1%) 5.5M to 5.45M | |
| 13-Mar-24 7:53 PM View: | Atlas Venture Fund X, L.P. 10% Owner | Kymera Therapeutics, Inc. (KYMR) | 13-Mar-24 | Sale (Planned) | 115,090 | $42.23 | $4,859,990.00 | (2%) 5.64M to 5.53M | |
| 13-Mar-24 7:52 PM View: | Booth Bruce Director | Kymera Therapeutics, Inc. (KYMR) | 13-Mar-24 | Sale (Planned) | 139,255 | $42.23 | $5,880,420.00 | (2%) 5.64M to 5.5M | |
| 13-Mar-24 7:53 PM View: | Atlas Venture Fund X, L.P. 10% Owner | Kymera Therapeutics, Inc. (KYMR) | 13-Mar-24 | Sale (Planned) | 24,165 | $42.23 | $1,020,420.00 | (< 1%) 5.53M to 5.5M | |
| 13-Mar-24 7:53 PM View: | Atlas Venture Fund X, L.P. 10% Owner | Kymera Therapeutics, Inc. (KYMR) | 12-Mar-24 | Sale (Planned) | 28,271 | $41.98 | $1,186,740.00 | (< 1%) 5.67M to 5.64M | |
| 13-Mar-24 7:52 PM View: | Booth Bruce Director | Kymera Therapeutics, Inc. (KYMR) | 12-Mar-24 | Sale (Planned) | 162,918 | $41.98 | $6,838,810.00 | (3%) 5.81M to 5.64M | |
| 13-Mar-24 7:53 PM View: | Atlas Venture Fund X, L.P. 10% Owner | Kymera Therapeutics, Inc. (KYMR) | 12-Mar-24 | Sale (Planned) | 134,647 | $41.98 | $5,652,070.00 | (2%) 5.81M to 5.67M | |
| 13-Mar-24 7:52 PM View: | Booth Bruce Director | Kymera Therapeutics, Inc. (KYMR) | 11-Mar-24 | Sale (Planned) | 51,184 | $42.85 | $2,193,150.00 | (< 1%) 5.86M to 5.81M | |
| 13-Mar-24 7:53 PM View: | Atlas Venture Fund X, L.P. 10% Owner | Kymera Therapeutics, Inc. (KYMR) | 11-Mar-24 | Sale (Planned) | 42,302 | $42.85 | $1,812,590.00 | (< 1%) 5.86M to 5.82M | |
| 13-Mar-24 7:53 PM View: | Atlas Venture Fund X, L.P. 10% Owner | Kymera Therapeutics, Inc. (KYMR) | 11-Mar-24 | Sale (Planned) | 8,882 | $42.85 | $380,562.00 | (< 1%) 5.82M to 5.81M | |
| 04-Mar-24 6:12 PM View: | Jacobs Bruce N. Chief Financial Officer | Kymera Therapeutics, Inc. (KYMR) | 04-Mar-24 | Sale | 3,934 | $41.86 | $164,664.00 | (3%) 146.28K to 142.35K | |
| 04-Mar-24 6:21 PM View: | Gollob Jared Chief Medical Officer | Kymera Therapeutics, Inc. (KYMR) | 04-Mar-24 | Sale | 3,344 | $41.86 | $139,967.00 | (3%) 99.08K to 95.74K | |
| 04-Mar-24 6:12 PM View: | Jacobs Bruce N. Chief Financial Officer | Kymera Therapeutics, Inc. (KYMR) | 01-Mar-24 | Grant | 31,250 | -- | -- | 27% 115.03K to 146.28K | |
| 04-Mar-24 6:15 PM View: | Chiniara Ellen Chief Legal Officer | Kymera Therapeutics, Inc. (KYMR) | 01-Mar-24 | Grant | 21,755 | -- | -- | 64% 34.2K to 55.96K | |
| 04-Mar-24 6:16 PM View: | Chadwick Jeremy G Chief Operating Officer | Kymera Therapeutics, Inc. (KYMR) | 01-Mar-24 | Grant | 13,425 | -- | -- | 40% 33.33K to 46.76K | |
| 04-Mar-24 6:21 PM View: | Gollob Jared Chief Medical Officer | Kymera Therapeutics, Inc. (KYMR) | 01-Mar-24 | Grant | 24,375 | -- | -- | 33% 74.71K to 99.08K | |
| 29-Feb-24 10:00 PM View: | Gollob Jared Chief Medical Officer | Kymera Therapeutics, Inc. (KYMR) | 27-Feb-24 | Planned Option Sale | 400 | $45.00 | $18,000.00 | (< 1%) 75.11K to 74.71K | |
| 29-Feb-24 10:00 PM View: | Gollob Jared Chief Medical Officer | Kymera Therapeutics, Inc. (KYMR) | 27-Feb-24 | Option Exercise | 400 | $2.08 | $832.00 | < 1% 74.71K to 75.11K | |
| 21-Feb-24 6:46 PM View: | Albers Jeffrey W. Director | Kymera Therapeutics, Inc. (KYMR) | 21-Feb-24 | Option Exercise | 4,385 | $10.34 | $45,340.90 | 100% 0 to 4.38K | |
| 21-Feb-24 6:46 PM View: | Albers Jeffrey W. Director | Kymera Therapeutics, Inc. (KYMR) | 21-Feb-24 | Planned Option Sale | 4,385 | $39.05 | $171,227.00 | (100%) 4.38K to 0 | |
| 21-Feb-24 6:46 PM View: | Albers Jeffrey W. Director | Kymera Therapeutics, Inc. (KYMR) | 20-Feb-24 | Option Exercise | 615 | $10.34 | $6,359.10 | 100% 0 to 0.61K | |
| 21-Feb-24 6:46 PM View: | Albers Jeffrey W. Director | Kymera Therapeutics, Inc. (KYMR) | 20-Feb-24 | Planned Option Sale | 615 | $39.07 | $24,030.90 | (100%) 0.61K to 0 | |
| 09-Feb-24 7:47 PM View: | Gollob Jared Chief Medical Officer | Kymera Therapeutics, Inc. (KYMR) | 09-Feb-24 | Option Exercise | 46,137 | $2.08 | $95,965.00 | 62% 74.71K to 120.85K | |
| 09-Feb-24 7:47 PM View: | Gollob Jared Chief Medical Officer | Kymera Therapeutics, Inc. (KYMR) | 09-Feb-24 | Planned Option Sale | 46,137 | $35.50 | $1,638,070.00 | (38%) 120.85K to 74.71K | |
| 23-Jan-24 7:37 PM View: | Albers Jeffrey W. Director | Kymera Therapeutics, Inc. (KYMR) | 23-Jan-24 | Option Exercise | 10,000 | $10.34 | $103,400.00 | 100% 0 to 10.0K | |
| 23-Jan-24 7:37 PM View: | Albers Jeffrey W. Director | Kymera Therapeutics, Inc. (KYMR) | 23-Jan-24 | Planned Option Sale | 10,000 | $30.05 | $300,470.00 | (100%) 10.0K to 0 | |
| 05-Jan-24 5:15 PM View: | Chiniara Ellen Chief Legal Officer | Kymera Therapeutics, Inc. (KYMR) | 04-Jan-24 | Sale | 3,295 | $22.58 | $74,415.60 | (9%) 37.5K to 34.2K | |
| 02-Jan-24 5:43 PM View: | Mainolfi Nello Chief Executive Officer Director | Kymera Therapeutics, Inc. (KYMR) | 02-Jan-24 | Option Exercise | 9,000 | $2.08 | $18,720.00 | 1% 606.57K to 615.57K | |
| 06-Nov-23 6:07 PM View: | Bvf Partners L P/il Director | Kymera Therapeutics, Inc. (KYMR) | 03-Nov-23 | Purchase | 197,699 | $14.07 | $2,781,410.00 | 4% 4.86M to 5.05M | |
| 06-Nov-23 6:00 PM View: | Mainolfi Nello Chief Executive Officer Director | Kymera Therapeutics, Inc. (KYMR) | 03-Nov-23 | Option Exercise | 20,000 | $2.08 | $41,600.00 | 3% 586.57K to 606.57K | |
| 06-Nov-23 6:07 PM View: | Bvf Partners L P/il Director | Kymera Therapeutics, Inc. (KYMR) | 02-Nov-23 | Private Purchase | 216,406 | $11.64 | $2,519,920.00 | 5% 4.64M to 4.86M | |
| 08-Aug-23 4:30 PM View: | Mainolfi Nello Chief Executive Officer Director | Kymera Therapeutics, Inc. (KYMR) | 08-Aug-23 | Option Exercise | 12,000 | $2.08 | $24,960.00 | 2% 574.57K to 586.57K |
